Research Methods in Drug Surveillance

Adverse drug reactions must be monitored, beginning with the development of a new drug, and continuing throughout its complete life cycle. During these various stages, different methods are necessary. This paper describes the advantages and disadvantages of common methods of collecting data on adverse drug reactions after a drug has been approved. We then concentrate on two drug surveillance projects, the Prescription Event Monitoring (PEM) of the Drug Surveillance Research Unit and the AMSP Project (”Arzneimittelsicherheit in der Psychiatrie”, Drug Safety in Psychiatry). AMSP is compared to cohort studies and spontaneous reporting systems on the one hand, and the specialised PEM project, on the other. The possible influence of various sources of bias is critically analysed.

References

• 1 Andrew J E, Prescott P, Smith T M, Inman W H, Kubota K. Testing for adverse reactions using prescription event monitoring.  Stat Med. 1996;  15 987-1002
• 2 Ashby D, Smyth R L, Brown P J. Statistical issues in pharmacoepidemiological case-control studies.  Stat Med. 1998;  17 1839-1850
• 3 CIOMS . Guidelines for Preparing Core Clinical Safety Information on Drugs. Report from CIOMS Working Group III. Genf; WHO 1995
• 4 Greil W, Horvath A, Sassim N, Erazo N, Grohmann R. Disinhibition of libido: an adverse effect of SSRI?.  J Affect Disord. 2001;  62 225-228
• 5 Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results.  Pharmacopsychiatry. 2004;  37 Suppl 1 S4-11
• 6 Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L G. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data.  Pharmacopsychiatry. 2004;  37 Suppl 1 S16-26
• 7 Heeley E, Riley J, Layton D, Wilton L V, Shakir S AW. Prescription-event monitoring and reporting of adverse drug reactions.  Lancet. 2001;  358 1872-1873
• 8 Heeley E, Wilton L V, Shakir S AW. Automated signal generation in Prescription-Event Monitoring.  Drug Safety. 2002;  25 423-432
• 9 Inman W HW. Monitoring for Drug Safety. Philadelphia; J. B. Lippincott Co 1980
• 10 Koster M C, Teeuw B, Cockburn I. Compliance in European pharmacovigilance: How compliant is compliant?.  Pharmacoepidemiology and Drug Safety. 2000;  9 473-478
• 11 Mann R D, Wilton L V, Pearce G L, Mackay F J, Dunn N R. Prescription-event monitoring (PEM) in 1996 - A method of non-interventional observational cohort pharmacovigilance.  Pharmacoepidemiology and Drug Safety. 1997;  6 (Suppl. 3) S5-11
• 12 Stübner S, Padberg F, Grohmann R, Hampel H, Hollweg M, Hippius H. et al . Pisa syndrome (Pleurothotonus): Report of a multicenter drug safety surveillance project.  J. Clin. Psychiatry. 2000;  61 569-574
• 13 Wolstein J, Grohmann R, Rüther E, Hippius H. Antipsychotic drugs and venous thromboembolism.  Lancet. 2000;  356 252